Glenmark Pharma reports Q3 FY25 PAT at Rs. 348 Cr

Glenmark’s consolidated revenue was at Rs. 3,387.6 crore as against Rs. 2,506.7 crore recording an increase of 35.1% YoY

Cosmo and Glenmark receives UK MHRA approval to market Winlevi in UK

Akums reports Q3 FY25 adjusted PAT at Rs. 66.3 Cr

Branded formulation business continues to perform well across domestic and export markets

Alembic Pharmaceuticals appoints Prag Goel as VP – Sales and Marketing (Megacare, Enteron and Osteofit business divisions)

He is an experienced professional in the pharmaceutical industry with about 30 years of progressive experience

Sun Pharma presents clinical efficacy and safety data in severe dermatological conditions at 2024 EADV Congress

The company will also share results in two additional posters for deuruxolitinib

10 year data for Merck’s Keytruda demonstrates sustained overall survival benefit versus Ipilimumab in advanced melanoma

At 10 years, more than one-third (34.0%) of patients with advanced melanoma were alive after treatment with KEYTRUDA, compared to 23.6% of patients treated with ipilimumab

DKSH partners with Hasten Biopharmaceutical’s growth in Thailand

Bayer Group posts 2Q 2024 sales up 3.1% at € 11.14 billion

Pharmaceuticals and Consumer Health report higher sales (Fx & portfolio adj.) and lower earnings

Aarti Drugs posts Q1 FY25 PAT lower at Rs. 33.3 Cr

Sun Pharmaceutical receives USFDA approval for oral JAK inhibitor ‘Leqselvi’

Leqselvi delivered statistically significant efficacy across two Phase 3 clinical trials